Inka Health's Breakthrough: Revolutionizing Pharmaceutical Analytics

In the ever-evolving landscape of pharmaceutical analytics, Onco-Innovations' subsidiary, Inka Health, has made a significant stride by completing analytical work for AstraZeneca Canada. This project, initiated under a service agreement from September 2024, has not only advanced pharmaceutical evidence generation but also paved the way for groundbreaking studies to be presented at ISPOR 2025 in Montréal. The implications of this achievement are far-reaching, potentially reshaping the way real-world evidence (RWE) is utilized in regulatory and market access decisions.

The collaboration between Inka Health and AstraZeneca Canada is a testament to the power of innovative methodologies in addressing key analytical challenges. The first study, titled "Addressing Bias and Generalizability Challenges in Non-Local Real-World Evidence Through Transportability Analyses," co-authored by Inka Health founders Paul Arora and Alind Gupta alongside AstraZeneca Canada, explores how advanced analytical approaches can mitigate bias and improve the generalizability of international data. This is crucial for regulators and pharmaceutical companies seeking to make informed decisions on treatments across diverse healthcare systems.



The second study, "A Comprehensive Review of Real-World Evidence (RWE) Use in Submissions to Canada's Drug Agency (CDA)," provides an in-depth evaluation of how RWE is utilized in regulatory submissions in Canada. By analyzing past submissions, the study sheds light on how often and in what ways RWE has influenced drug approvals, helping to shape more efficient and evidence-based regulatory strategies. These findings highlight the growing role of data-driven insights in optimizing drug evaluation processes and regulatory strategies.

The successful completion of this project and the upcoming presentations at ISPOR 2025 in Montréal on May 16, 2025, from 9:00-11:30 AM ET, will showcase key findings and their impact on the use of RWE in pharmaceutical research. This exposure will attract more clients and partners, driving future growth for Onco-Innovations. The integration of advanced causal inference techniques into Inka Health's proprietary analytics platform, SynoGraph, further strengthens its role in advancing evidence generation and precision medicine.

The financial implications for Onco-Innovations and Inka Health following the successful integration of advanced causal inference techniques into SynoGraph are significant. The enhanced credibility and applicability of RWE through transportability analyses can lead to more informed decision-making by regulators and pharmaceutical companies. This can result in faster and more efficient drug approval processes, which is beneficial for pharmaceutical companies seeking market access for their products. The incorporation of advanced causal inference techniques into SynoGraph can strengthen Inka Health's role in advancing evidence generation and precision medicine, leading to new partnerships and collaborations with industry leaders. Such partnerships can result in additional revenue streams for Onco-Innovations and Inka Health, as well as increased visibility and credibility in the pharmaceutical analytics space.

In conclusion, the completion of the analytical work for AstraZeneca Canada by Inka Health significantly enhances Onco-Innovations' market position and future growth prospects in the pharmaceutical analytics sector. The integration of advanced causal inference techniques into SynoGraph, along with the upcoming presentations at ISPOR 2025, will further solidify Inka Health's role as a leader in pharmaceutical analytics. The potential financial implications, including increased demand for their services, new partnerships and collaborations, and enhanced reputation and credibility, make this a pivotal moment for Onco-Innovations and Inka Health.